Teva unveils new pipeline assets from its 2013 NTE program

5 December 2013

Best known as the world’s biggest generic drugmaker, Israel’s Teva Pharmaceutical Industries (NYSE:TEVA) yesterday announced that 15 new projects have entered its development pipeline from its New Therapeutic Entities (NTE) program.

Launched one year ago by then chief executive Jeremy Levin who stepped down from the post this October, the NTE program has delivered new pipeline assets in major therapeutic areas, comprising: new therapeutic entities includes four abuse-deterrent pain drugs, two schizophrenia treatments, and medicines for Crohn’s disease, Parkinson’s and HIV. “Risk-adjusted” sales will be $1 billion to $1.5 billion by 2018, and $3 billion by 2020, the company said.

Adjusting to Copaxone decline

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK